Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models

A crucial question in polyQ-induced neurodegeneration is the influence of wild type protein on the formation of aggregates and toxicity. Recently it was shown that non-expanded ataxin-3 protein mitigated neurodegeneration in a Drosophila and mouse model of SCA3. We now explored the effects of overex...

Full description

Bibliographic Details
Main Authors: Jeannette Hübener, Olaf Riess
Format: Article
Language:English
Published: Elsevier 2010-04-01
Series:Neurobiology of Disease
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0969996110000070
_version_ 1818573136798416896
author Jeannette Hübener
Olaf Riess
author_facet Jeannette Hübener
Olaf Riess
author_sort Jeannette Hübener
collection DOAJ
description A crucial question in polyQ-induced neurodegeneration is the influence of wild type protein on the formation of aggregates and toxicity. Recently it was shown that non-expanded ataxin-3 protein mitigated neurodegeneration in a Drosophila and mouse model of SCA3. We now explored the effects of overexpressing non-expanded ataxin-3 with 15Q in a SCA3 transgenic mouse model with 70 polyglutamine repeats. These double-transgenic mice (dt) developed neurological symptoms with premature death at the age of 6 months comparable to the single-transgenic (st) SCA3 disease model. Furthermore, immunohistochemistry revealed similar localization and distribution of nuclear aggregates in dt- and st-mutant SCA3 mice. In a second dt-mutant mouse model, coexpression of ataxin-3 with 148Q attached to a nuclear export signal, which usually diminishes the phenotype, did even reinforce toxic effects of mutant expanded ataxin-3. We therefore conclude that overexpressing wild type ataxin-3 or mutant ataxin-3 with NES are not striking suppressors of polyglutamine-induced neurodegeneration and have thus no potential for future gene therapeutic interventions in SCA3.
first_indexed 2024-12-15T00:07:03Z
format Article
id doaj.art-effbf59e43104dba89300fbe38efacbe
institution Directory Open Access Journal
issn 1095-953X
language English
last_indexed 2024-12-15T00:07:03Z
publishDate 2010-04-01
publisher Elsevier
record_format Article
series Neurobiology of Disease
spelling doaj.art-effbf59e43104dba89300fbe38efacbe2022-12-21T22:42:42ZengElsevierNeurobiology of Disease1095-953X2010-04-01381116124Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse modelsJeannette Hübener0Olaf Riess1Corresponding author. Department of Medical Genetics, University of Tuebingen, Calwerstrasse 7, 72076 Tuebingen, Germany. Fax: +49 7071 295171.; Department of Medical Genetics, University of Tuebingen, Tuebingen, GermanyDepartment of Medical Genetics, University of Tuebingen, Tuebingen, GermanyA crucial question in polyQ-induced neurodegeneration is the influence of wild type protein on the formation of aggregates and toxicity. Recently it was shown that non-expanded ataxin-3 protein mitigated neurodegeneration in a Drosophila and mouse model of SCA3. We now explored the effects of overexpressing non-expanded ataxin-3 with 15Q in a SCA3 transgenic mouse model with 70 polyglutamine repeats. These double-transgenic mice (dt) developed neurological symptoms with premature death at the age of 6 months comparable to the single-transgenic (st) SCA3 disease model. Furthermore, immunohistochemistry revealed similar localization and distribution of nuclear aggregates in dt- and st-mutant SCA3 mice. In a second dt-mutant mouse model, coexpression of ataxin-3 with 148Q attached to a nuclear export signal, which usually diminishes the phenotype, did even reinforce toxic effects of mutant expanded ataxin-3. We therefore conclude that overexpressing wild type ataxin-3 or mutant ataxin-3 with NES are not striking suppressors of polyglutamine-induced neurodegeneration and have thus no potential for future gene therapeutic interventions in SCA3.http://www.sciencedirect.com/science/article/pii/S0969996110000070Ataxin-3Disease modificationDouble-transgenic miceMouse modelPolyglutamine diseaseSpinocerebellar ataxia type 3
spellingShingle Jeannette Hübener
Olaf Riess
Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models
Neurobiology of Disease
Ataxin-3
Disease modification
Double-transgenic mice
Mouse model
Polyglutamine disease
Spinocerebellar ataxia type 3
title Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models
title_full Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models
title_fullStr Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models
title_full_unstemmed Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models
title_short Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: Conclusions from double-transgenic mouse models
title_sort polyglutamine induced neurodegeneration in sca3 is not mitigated by non expanded ataxin 3 conclusions from double transgenic mouse models
topic Ataxin-3
Disease modification
Double-transgenic mice
Mouse model
Polyglutamine disease
Spinocerebellar ataxia type 3
url http://www.sciencedirect.com/science/article/pii/S0969996110000070
work_keys_str_mv AT jeannettehubener polyglutamineinducedneurodegenerationinsca3isnotmitigatedbynonexpandedataxin3conclusionsfromdoubletransgenicmousemodels
AT olafriess polyglutamineinducedneurodegenerationinsca3isnotmitigatedbynonexpandedataxin3conclusionsfromdoubletransgenicmousemodels